Cixutumumab: all 40 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory SarcomaCompletedNCT01614795Phase 2Results posted
• Cixutumumab in Treating Patients With Metastatic Melanoma of the EyeCompletedNCT01413191Phase 2Results posted
• BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung CancerCompletedNCT01263782Phase 2Results posted
• A Study in Non-Small Cell Lung CancerCompletedNCT01232452Phase 2Results posted
• Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With ChemotherapyCompletedNCT01160458Phase 2Results posted
• Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction CancerActive, not recruitingNCT01142388Phase 2Results posted
• Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate CancerCompletedNCT01120236Phase 2Results posted
• Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic RhabdomyosarcomaCompletedNCT01055314Phase 2Results posted
• Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate CancerCompletedNCT01026623Phase 1/2Results posted
• Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone SarcomaCompletedNCT01016015Phase 2Results posted
• A Study of IMC-A12 in Advanced Solid TumorsCompletedNCT01007032Phase 1Results posted
• Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00986674Phase 2Results posted
• Preoperative Treatment With Cetuximab and/or IMC-A12CompletedNCT00957853Phase 2Results posted
• Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerTerminatedNCT00955305Phase 2Results posted
• A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the LiverCompletedNCT00906373Phase 2Results posted
• A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive StageCompletedNCT00887159Phase 2Results posted
• A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy BeforeCompletedNCT00870870Phase 2Results posted
• A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and BevacizumabTerminatedNCT00845039Phase 2Results posted
• Cixutumumab in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00831844Phase 2Results posted
• A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is AvailableCompletedNCT00785538Phase 1Results posted
• A Study of Cixutumumab (IMC-A12) in Islet Cell CancerCompletedNCT00781911Phase 2Results posted
• IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by SurgeryTerminatedNCT00778817Phase 2Results posted
• Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00778167Phase 1/2Results posted
• Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast CancerCompletedNCT00699491Phase 1/2Results posted
• Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast CancerCompletedNCT00684983Phase 2Results posted
• A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate CancerCompletedNCT00683475Phase 2Results posted
• A Five-Tier, Open-Label Study of IMC-A12 in Advanced SarcomaCompletedNCT00668148Phase 2Results posted
• IMC-A12 in Treating Patients With Advanced Liver CancerCompletedNCT00639509Phase 2Results posted
• S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00617708Phase 1/2Results posted
• Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate CancerCompletedNCT00520481Phase 2Results posted
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
• A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid TumorsWithdrawnNCT01182883Phase 1
• Selumetinib and Cixutumumab in Treating Patients With Advanced Solid MalignanciesCompletedNCT01061749Phase 1
• Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver CancerCompletedNCT01008566Phase 1
• Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to TreatmentCompletedNCT00880282Phase 1
• A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is AvailableCompletedNCT00785941Phase 1
• Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate CancerCompletedNCT00769795Phase 2
• Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue SarcomaCompletedNCT00720174Phase 1
• Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic CancerCompletedNCT00678769Phase 1
• IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid TumorCompletedNCT00609141Phase 1

← Cixutumumab overview